259 related articles for article (PubMed ID: 36319063)
1. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
Chen Y; Jia M; Wang S; Xu S; He N
Front Immunol; 2022; 13():835690. PubMed ID: 35251028
[TBL] [Abstract][Full Text] [Related]
3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
4. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
5. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
[TBL] [Abstract][Full Text] [Related]
6. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
7. Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.
Chen X; Hamano R; Subleski JJ; Hurwitz AA; Howard OM; Oppenheim JJ
J Immunol; 2010 Jul; 185(1):174-82. PubMed ID: 20525892
[TBL] [Abstract][Full Text] [Related]
8. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
9. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
[TBL] [Abstract][Full Text] [Related]
10. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
[TBL] [Abstract][Full Text] [Related]
11. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.
Chen X; Subleski JJ; Kopf H; Howard OM; Männel DN; Oppenheim JJ
J Immunol; 2008 May; 180(10):6467-71. PubMed ID: 18453563
[TBL] [Abstract][Full Text] [Related]
12. TNFR2 deficiency impairs the growth of mouse colon cancer.
Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X
Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938
[No Abstract] [Full Text] [Related]
13. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
14. Aberrant frequency of TNFR2-expressing CD4+ FoxP3+ regulatory T cells in nasopharyngeal carcinoma patients.
Engku Abd Rahman ENS; Irekeola AA; Shueb RH; Mat Lazim N; Mohamud R; Chen X; Ghazali L; Awang NMSH; Haron A; Chan YY
Cytokine; 2023 Oct; 170():156341. PubMed ID: 37657236
[TBL] [Abstract][Full Text] [Related]
15. TNFR2-expressing CD4
He J; Li R; Chen Y; Hu Y; Chen X
Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis.
Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q
Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159
[TBL] [Abstract][Full Text] [Related]
17. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment.
Chen X; Wu X; Zhou Q; Howard OM; Netea MG; Oppenheim JJ
J Immunol; 2013 Feb; 190(3):1076-84. PubMed ID: 23277487
[TBL] [Abstract][Full Text] [Related]
18. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
19. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo.
Zhou Q; Hu Y; Howard OM; Oppenheim JJ; Chen X
Cytokine; 2014 Jan; 65(1):56-64. PubMed ID: 24080164
[TBL] [Abstract][Full Text] [Related]
20. Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4
He T; Zhao Y; Zhao P; Zhao L; Zakaria J; Wang K
Int Immunopharmacol; 2022 Jul; 108():108823. PubMed ID: 35623290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
